3M, a diversified technology company, announced Wednesday its acquisition of Acolyte Biomedica Ltd., a Salisbury, U.K.-based provider of an automated microbial detection platform that aids in the rapid detection, diagnosis, and treatment of infectious diseases.
Acolyte Biomedica helps hospitals control high-risk infections through improved screening and targeted treatment of methicillin-resistant Staphylococcus aureus (MRSA), a type of bacteria that is resistant to certain antibiotics and occurs most frequently in hospital patients who have weakened immune systems.
According to Chuck Kummeth, division vice president, 3M Medical Division, the acquisition of Acolyte Biomedica allows 3M to continue expanding into its core infection prevention business.
3M's infection prevention portfolio includes diagnostic testing, sterilization assurance, skin preparation, sterile field and surface, wound management and environmental cleaning.
Acolyte Biomedica employs 13 people at its facility in Salisbury.
